Atomic high-tech new drug research and development brings good news again - Class one innovative dru

On December twenty-fourth, the Class one innovative drug "Fluorine [eighteenF] Pyrylamide Injection" developed by Atomic High Tech, a subsidiary of China Tongfu, successfully passed the review and was officially approved by the National Medical Products Administration (NMPA) to conduct clinical trials. Fluorine [eighteenF] pyridine amide injection is a positron emission tomography (PET) imaging agent that can rapidly bind with melanoma in vivo, with good specificity and high sensitivity, significantly improving the accuracy of melanoma diagnosis and staging, and providing precise basis for clinical treatment decisions. Melanoma is a type of malignant tumor that originates from melanocytes in the neural crest, with common primary sites including the plantar, toe, fingertip, and submandibular extremities. Melanoma is a highly malignant tumor with a high mortality. According to statistics, the incidence rate is also increasing year by year in recent years, so timely and accurate diagnosis is crucial for the treatment of melanoma. In December two thousand twenty-two, Atomic High Tech introduced the patent for fluorine [eighteenF] pyridine amide compound from Tongji Medical College Affiliated Union Hospital of Huazhong University of Science and Technology, and quickly carried out product conversion work. With strong support from the National Defense Science and Technology Industry Administration, China National Nuclear Corporation, Beijing Science and Technology Commission, and Zhongguancun Science and Technology Park Management Committee, Atomic High Tech has successfully completed preclinical research on chemical precursors and formulations, submitted clinical trial applications to the National Medical Products Administration, and successfully obtained approval to conduct clinical trials. Atomic High Tech will strictly adhere to the requirements of the National Medical Products Administration, uphold the responsibilities of a central enterprise and the corporate mission of "strengthening the nuclear power and benefiting humanity" in the nuclear industry, accelerate the clinical research work of fluoride [eighteenF] pyridine amide injection, and promote its early market launch, making greater contributions to significantly increasing the accuracy of melanoma diagnosis, benefiting patients, and serving the "Healthy China" strategy. (China Same Radiation)